Priv.-Doz. Dr. med. Bernhard Kreymann, nephrologist and founder of Hepa Wash GmbH, has been working on the topic of liver and multi-organ support since 1994. During his time at the Munich University Hospital Rechts der Isar, he invented single-pass albumin dialysis in 1995, which is still used today to stabilize patients until liver transplantation. However, the method is not effective or inexpensive enough to be used more widely in everyday clinical practice.
Due to the high financial requirements, further development of a single pass albumin dialysis could not be done at the university. As a result, Hepa Wash was founded as a one-man start-up in a research lab in Garching near Munich in mid-2005. The development of the company was made possible over the years by means of several financing rounds by private investors, KfW banking groups and employees. The idea was to implement effective liver support therapy from concept to marketing. Not only has that goal been achieved, but today’s ADVOS procedure is suitable both for hepatic dialysis and is the first method in the world for extended and individualized support of the main detoxification organs: the liver, lungs and kidneys.
The versatility and complexity of the human organism regularly presents medicine with therapeutic challenges for reliable treatment options for patients in intensive care all over the world.
We are looking for reliable treatment methods to close the therapeutic gap in multi-organ failure.
Since its founding in 2005, Hepa Wash has devoted itself to the development of effective multi-organ support.
We are developing novel medical products with a focus on patient safety and user-friendliness.
The most advanced medical and engineering art in a safe, functional and user-friendly product, the ADVOS multi has achieved the originally set goal after numerous in-vitro tests, pre-clinical and clinical studies: the ADVOS procedure was approved in Europe and clinical users have given it a clear and positive response.
Leading university clinics nationwide work with the promising approach of the ADVOS procedure.
Hepa Wash takes 3rd place in the Munich Business Plan competition.
A laboratory prototype of the dialysis machine is being built.
Start of research in the laboratories at the Garching Research Campus.
“HepaClean” funding program – basic establishment of the Hepa Wash process, in cooperation with the biochemistry and medical technology chair of the TU Munich. Hepa Wash is supported by the Bavarian Research Foundation with EUR 300,000.
Hepa Wash takes 3rd place in the Science4Life Business Plan competition.
Founders, private investors and Bayern Kapital invest a total of EUR 300,000 as starting capital.
Foundation of Hepa Wash GmbH by Dr. Bernhard Kreymann.
Hepa Wash is awarded 2nd place at the New Venture Competition at Harvard Business School, USA.
Start of the in-vitro tests of the Hepa Wash procedure.
The Ethics Council of the Hospital Rechts der Isar gives consent for the preclinical studies in acute liver failure.
A prototype of the dialysis machine for the preclinical study is being developed.
For the pre-clinical studies, partners are found at the University Hospital Rechts der Isar in Munich.
The Bavarian Ministry of Economic Affairs grants funding of EUR 120,000 from the BayTOU funding program.
The efficacy of the Hepa Wash process at that time can be demonstrated in-vitro.
Relocation of the company to the Munich Technology Centre.
Hepa Wash and the department of Gastroenterology at the University Hospital Rechts der Isar, receives EUR 425,000 from the Bavarian Research Fund for the preclinical study “Patal – Pathogenesis and Therapy of Acute Liver Failure”.
In various in-vivo trials, it can be shown that the Hepa Wash method reduces the mortality rate in acute liver failure. An improvement in the most important organ functions can be achieved.
The Bavarian Ministry of Economic Affairs grants EUR 770,000 to promote the development of the innovative liver dialysis procedure.
Start of development and construction of the human prototype.
Opening of the new laboratory and workshop area in the Munich Technology Centre (MTZ).
TÜV Süd certifies that the human prototype is safe according to the Medical Devices Directive MDD 93/42 EEC.
The Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices) (BfArM) approved the first two clinical trials for the release of the former Hepa Wash procedure.
The Ethics Council of the Munich University Hospital Rechts der Isar approves the clinical examination of Hepa Wash procedure.
Hepa Wash reaches 4th place in the final of the Eurecan European Venture Contest in Barcelona.
The Federal Ministry of Economics and Technology promotes the development of an in-house production of treatment fluids with EUR 125,000 from the “Central Innovation Program Fund”.
The quality management system is certified according to ISO 13485 by TÜV Süd.
Hepa Wash GmbH is a “Selected Place” and a prize-winner in the “365 Landmarks in the Land of Ideas” competition.
Expansion of in-house production of treatment concentrates.
Expansion of the production area and warehouse at the Munich Technology Centre (MTZ).
The developed dialysis machine (LK2001) and the treatment concentrates are certified according to Medical Device Directive (MDD) 93/42 EEC Annex II.3 and are therefore market-approved in Europe.
The company has 26 permanent employees covering all business areas.
Second place at the Venture Lounge LifeScience & MedTech in Munich for an excellent company presentation and a convincing business plan.
Participation in the Innovation Days 2014 in Paris and placement among the 15 finalists for the Innovation Prize.
Membership in the Cluster Mechatronics & Automation eV.
Participation in the Healthtech Summit in Lausanne with a company presentation.
Second place in the “Most Innovative Product” category of the Senetics Innovation Award 2014.
Contributed to the subject “Liver Support Therapy” in the published textbook “Specialist Nephrology and Dialysis”.
Hepa Wash celebrates its 10th birthday.
Selected exhibitor of the “Walk of Future” at the event “Future Council of the Bavarian Economy: what Bavaria needs tomorrow!”
Participation with company presentation at the HealthTech Growth Academy in Aarhus, Denmark.
The ADVOS procedure is used in 10 German University clinics.
Renaming the multi-organ support unit from LK2001 to ADVOS multi.
Staff increase to 35 employees.
Establishment of further clinical centers.
Setup of Sales and Marketing organization in Germany.
First international presence.
Collaboration with German Accelerator Life Sciences to Prepare U.S. Expansion.